Please use this identifier to cite or link to this item:

TitleCurcumin ameliorates the targeted delivery of methotrexate intercalated montmorillonite clay to cancer cells
Author(s)Kar, S.
Kundu, Banani
Reis, R. L.
Sarkar, R.
Nandy, P.
Basu, R.
Das, S.
KeywordsAugmented therapy
Folate receptor
Montmorillonite clay
Sustain release
Issue dateJul-2019
JournalEuropean Journal of Pharmaceutical Sciences
CitationKar S., Kundu B., Reis R. L., Sarkar R., Nandy P., Basu R., Das S. Curcumin ameliorates the targeted delivery of methotrexate intercalated montmorillonite clay to cancer cells , Eur J Pharm Sci., Vol. 135, pp. 91-102, doi:10.1016/j.ejps.2019.05.006, 2019
Abstract(s)Montmorillonite Clay (MMT) is aimed to develop as an orally administrable drug delivery vehicle with enhanced efficacy. Aiming to enhance the therapeutic index of methotrexate, curcumin is concomitantly used with methotrexate in the present study. Being folate antagonist in nature, methotrexate is internalized into cells by folate receptor (FR); which is over-expressed in certain human cancer cells such as cervical carcinoma cells (HeLa). Firstly, montmorillonite Clay (MMT) is organically modified (OMMT) with cetyl trimethyl ammonium bromide (CTAB) and used to intercalate curcumin and methotrexate separately, designated as OMMT-Cur and OMMT-MTX, respectively. XRD pattern demonstrated successful intercalation of therapeutics and an increase in clay interlayer distance facilitated by CTAB. The dissolution kinetics of methotrexate follows Higuchi model for both Simulated Gastric Fluid (SGF) and Simulated Intestinal Fluid (SIF), while the release kinetics for curcumin fitted into Higuchi model for SGF and Hixson-Crowell model for SIF, respectively. OMMT-MTX are able to discriminate FR-positive HeLa cells from FR-negative breast cancer cells (MCF7); irrespective of alike cellular phenotypes. Further, the pre-treatment of HeLa cells with curcumin improves its sensitivity towards metho- trexate causing a greater killing of the Hela cells. Together, the results propose the concomitant use of curcumin and methotrexate for successfully targeting highly invasive FR-positive carcinomas by means of folate receptor using MMTs.
Publisher version
AccessRestricted access (UMinho)
Appears in Collections:3B’s - Artigos em revistas/Papers in scientific journals

Files in This Item:
File Description SizeFormat 
19862-Kar et al_Eur J Pharma Sci_2019_1_91-102.pdf
  Restricted access
4,45 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID